Annual Accounts Receivable
$6.29 M
-$93.75 M-93.72%
December 31, 2024
Summary
- As of March 13, 2025, LEGN annual accounts receivable is $6.29 million, with the most recent change of -$93.75 million (-93.72%) on December 31, 2024.
- During the last 3 years, LEGN annual accounts receivable has fallen by -$44.12 million (-87.53%).
- LEGN annual accounts receivable is now -93.72% below its all-time high of $100.04 million, reached on December 31, 2023.
Performance
LEGN Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Receivable
$6.29 M
+$5.58 M+791.77%
December 31, 2024
Summary
- As of March 13, 2025, LEGN quarterly accounts receivable is $6.29 million, with the most recent change of +$5.58 million (+791.77%) on December 31, 2024.
- Over the past year, LEGN quarterly accounts receivable has dropped by -$93.75 million (-93.72%).
- LEGN quarterly accounts receivable is now -93.72% below its all-time high of $100.04 million, reached on December 31, 2023.
Performance
LEGN Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
LEGN Accounts Receivable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -93.7% | -93.7% |
| 3 y3 years | -87.5% | -93.7% |
| 5 y5 years | -79.0% | -93.7% |
LEGN Accounts Receivable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -93.7% | +6885.6% | -93.7% | >+9999.0% |
| 5 y | 5-year | -93.7% | +6885.6% | -93.7% | -100.0% |
| alltime | all time | -93.7% | +6885.6% | -93.7% | -100.0% |
Legend Biotech Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | $6.29 M(-93.7%) | $6.29 M(+791.8%) |
| Sep 2024 | - | $705.00 K(-94.6%) |
| Jun 2024 | - | $13.06 M(+295.0%) |
| Mar 2024 | - | $3.31 M(-96.7%) |
| Dec 2023 | $100.04 M(>+9900.0%) | $100.04 M(>+9900.0%) |
| Sep 2023 | - | $20.00 K(-99.9%) |
| Jun 2023 | - | $15.06 M(>+9900.0%) |
| Mar 2023 | - | $56.00 K(-37.8%) |
| Dec 2022 | $90.00 K | $90.00 K(-80.5%) |
| Jun 2022 | - | $461.00 K(-99.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2022 | - | $50.45 M(+0.1%) |
| Dec 2021 | $50.41 M(-32.8%) | $50.41 M(+3258.4%) |
| Sep 2021 | - | $1.50 M(>+9900.0%) |
| Mar 2021 | - | $0.00(-100.0%) |
| Dec 2020 | $75.00 M(+150.1%) | $75.00 M(>+9900.0%) |
| Sep 2020 | - | $0.00(0.0%) |
| Jun 2020 | - | $0.00(0.0%) |
| Mar 2020 | - | $0.00(-100.0%) |
| Dec 2019 | $29.99 M(+14.4%) | $29.99 M |
| Dec 2018 | $26.22 M | - |
FAQ
- What is Legend Biotech annual accounts receivable?
- What is the all time high annual accounts receivable for Legend Biotech?
- What is Legend Biotech annual accounts receivable year-on-year change?
- What is Legend Biotech quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Legend Biotech?
- What is Legend Biotech quarterly accounts receivable year-on-year change?
What is Legend Biotech annual accounts receivable?
The current annual accounts receivable of LEGN is $6.29 M
What is the all time high annual accounts receivable for Legend Biotech?
Legend Biotech all-time high annual accounts receivable is $100.04 M
What is Legend Biotech annual accounts receivable year-on-year change?
Over the past year, LEGN annual accounts receivable has changed by -$93.75 M (-93.72%)
What is Legend Biotech quarterly accounts receivable?
The current quarterly accounts receivable of LEGN is $6.29 M
What is the all time high quarterly accounts receivable for Legend Biotech?
Legend Biotech all-time high quarterly accounts receivable is $100.04 M
What is Legend Biotech quarterly accounts receivable year-on-year change?
Over the past year, LEGN quarterly accounts receivable has changed by -$93.75 M (-93.72%)